Cancers with high GLUT1 expression had higher Eaverage (mean, 85.4 kPa vs 125.5 kPa, p <  0.001) and Eratio (mean, 11.7 vs 17.9, p <  0.001) and higher rates of ER negativity (21.7% vs 78.3%, p = 0.001), PR negativity (26.4% vs 73.1%, p = 0.004), HER2 positivity (25.0% vs 75.0%, p = 0.026), Ki67 positivity (31.7%% vs 68.3%, p = 0.001), grade 3 cancer (28.6% vs 71.4%, p = 0.005), and HER2-overexpressing (25.0% vs 75.0%) and triple-negative (23.1% vs 76.9%) subtypes (p = 0.001). The gene discussed is SLC2A1; the disease is cancer.